Expertise in
11
conditions

Atsumasa Komori

Omura, JP 
Expertise in
11
conditions
Omura, JP 

Overview

Atsumasa Komori practices practicing medicine in Omura, Japan.

Komori is highly rated in 11 conditions, according to our data. Their clinical expertise encompasses Primary Biliary Cholangitis, Autoimmune Hepatitis, Cholestasis, Cholangitis, and Liver Transplant.

They are actively involved in clinical research, co-authoring 81 peer reviewed articles and participating in 5 clinical trials.

Locations

Omura, Japan
Other Locations
Nagasaki, Japan
Oita, Japan
Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Enrollment Status: Completed
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: June 22, 2026
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
Enrollment Status: Completed
Publish Date: May 02, 2024
Intervention Type: Drug
Study Drugs: GSK3228836, PegIFN, NA therapy
Study Phase: Phase 2
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

81 Total Publications

On-Treatment Reassessment of Type IV Collagen 7S and M2BPGi-Qt Improves Long-Term Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis B.
On-Treatment Reassessment of Type IV Collagen 7S and M2BPGi-Qt Improves Long-Term Hepatocellular Carcinoma Risk Stratification in Chronic Hepatitis B.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 24, 2026

Frequently Asked Questions about Atsumasa Komori

Is Atsumasa Komori a top-rated expert for Primary Biliary Cholangitis?

MediFind is an objective health platform that identifies experts based on real-world data. Atsumasa Komori is classified as an Elite expert for Primary Biliary Cholangitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Atsumasa Komori participate in research or clinical trials?

Yes. Atsumasa Komori has published 81 articles and abstracts on conditions like Primary Biliary Cholangitis. You can view a list of Atsumasa Komori's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Komori's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile